Get notified when NNVC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Development Stage Company That Has No Products Approved For Commercial Sale, Never Generated Any Revenues (new) — The company is pre-revenue with no approved products, indicating high business risk.
- Accumulated Deficit of Approximately $149 Million At June 30, 2025 (new) — Large accumulated deficit signals ongoing losses and reliance on external financing.
- Cash and Cash Equivalent Balance of Approximately $1.6 Million (new) — Very low cash balance raises going concern risk, especially given the company's burn rate.
- Immediate Dilution of $1.02 Per Share to New Investors (new) — New investors pay $1.53 for shares with a net tangible book value of only $0.51, resulting in significant dilution.
NanoViricides prices $3.7M registered direct offering at $1.53/share; net proceeds $3.5M
Filed July 27, 2026 · ~1 min read
Key Changes
-
high
NanoViricides is selling 2,416,339 shares at $1.53 each, raising $3.7M gross; after fees, net proceeds to the company are $3.5M.
The Offering verify on EDGAR → -
medium
The offering also includes pre-funded warrants for 100,000 shares at $1.52999 and common warrants for 2,516,339 shares at $1.75.
The Offering verify on EDGAR → -
high
New investors face immediate dilution of $1.02 per share, as the adjusted net tangible book value after the offering is $0.51 per share.
Dilution verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade NNVC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify